Search results
Showing 1321 to 1335 of 1809 results for nice guidelines
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy.
View recommendations for MTG47Show all sections
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
Discontinued [GID-TAG414]
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.
For any queries, please contact qualitystandards@nice.org.ukDiscontinued [GID-NG10053]
Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.
Hyperglycaemia in acute coronary syndromes: management (CG130)
This guideline has been replaced by NICE guideline NG185.
Immunisations: reducing differences in uptake in under 19s (PH21)
This guideline has been replaced by NICE guideline NG218.
This guideline has been replaced by NICE guideline NG194.
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
This guideline has been updated and replaced by NICE guideline NG233.
This guideline has been updated and replaced by NICE guideline NG201.